MBX Biosciences (MBX) vs Nurix Therapeutics (NRIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MBX Biosciences (MBX) has outperformed Nurix Therapeutics (NRIX) over the past year, gaining 245.2% versus a gain of 131.2%. MBX Biosciences is the larger company by market cap ($2.55 billion vs $2.25 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MBX | NRIX |
|---|---|---|
| Share price | $53.01 | $21.69 |
| Market cap | $2.55B | $2.25B |
| 1-day change | -2.77% | -4.58% |
| YTD return | +72.92% | +19.82% |
| 1-year return | +245.19% | +131.23% |
| 5-year return | — | -21.16% |
| EPS (TTM) | $-2.37 | $-3.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-87.00M | — |
| 52-week high | $72.64 | $28.23 |
| 52-week low | $12.94 | $9.00 |
| Distance from 52-week high | -27.02% | -23.17% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +77.89% | +56.43% |
| Average volume | 539.34K | 1.27M |
| Shares outstanding | 48.16M | 103.78M |
| Employees | 63 | 317 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MBX has outperformed NRIX by 114.0 percentage points over the past year.
About MBX Biosciences
MBX stock →MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
About Nurix Therapeutics
NRIX stock →Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees
MBX vs NRIX FAQ
Which is bigger, MBX Biosciences or Nurix Therapeutics?
MBX Biosciences (MBX) is larger, with a market capitalization of $2.55B compared with $2.25B for Nurix Therapeutics (NRIX).
Which stock has performed better over the past year, MBX or NRIX?
MBX returned +245.19% over the past 12 months, compared with +131.23% for NRIX (price return, excluding dividends). Past performance does not predict future results.
Are MBX Biosciences and Nurix Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.